Radius health announces commercial agreement with paladin labs for abaloparatide in canada

Boston, jan. 05, 2021 (globe newswire) -- radius health, inc. (“radius” or the “company”) (nasdaq: rdus) today announced that the company has entered into definitive agreements with endo ventures limited, a subsidiary of endo international plc (“endo”) (nasdaq: endp), to register, commercialize, and distribute abaloparatide on an exclusive basis in canada. paladin labs inc. (“paladin”), an operating company of endo, will be responsible for all commercial activities related to abaloparatide. under the terms of the agreements, paladin will pay radius upfront and milestone payments up to approximately $8.0 million and tiered royalties up to the mid-twenties on net sales in canada.
RDUS Ratings Summary
RDUS Quant Ranking